Close Menu

CMS

The pandemic has underscored the importance of "bringing the trial to the patient," a concept that is likely to persist, particularly in precision oncology.

In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.

The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.

The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer. 

CMS has attempted to address stakeholders' concerns about its coverage criteria for germline NGS testing in a new proposed national policy.

In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.  

CMS had received significant stakeholder feedback that germline NGS testing is not the same as somatic testing, and that the NCD as written would negatively impact patients.

The agency said it is sensitive to stakeholder concerns and is working with MACs to adjust claims processing systems.

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

In a letter to CMS, AMP made a case for crosswalking existing CPT codes for BRCA1/2 testing to codes that more accurately reflect the work required to analyze these genes.

Pages